Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2025-04-14 Regulatory Filings
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
The European Commission to make final decision on EU Marketing Authorisation for lecanemab
Regulatory Filings Classification · 1% confidence The document is a press release from BioArctic AB regarding the status of a Marketing Authorisation Application (MAA) for the drug lecanemab with the European Commission. It provides an update on regulatory proceedings and the company's ongoing collaboration with Eisai. As it is a general regulatory announcement regarding company operations and regulatory status that does not fit into specific categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2025-04-14 English
The European Commission refers lecanemab decision to Appeal Committee
Regulatory Filings Classification · 1% confidence The document is a press release issued by BioArctic AB regarding a regulatory update on the marketing authorization process for their drug lecanemab in the EU. It details the referral of the decision to the Appeal Committee. This is a corporate announcement regarding regulatory developments and does not fit into specific categories like financial reports, dividends, or director dealings. Therefore, it is classified as a general regulatory filing.
2025-04-01 English
EU-kommissionen hänskjuter beslut om lecanemab till omprövningskommittén
Legal Proceedings Report Classification · 1% confidence The document is a press release from BioArctic AB regarding a regulatory update on the drug lecanemab, specifically concerning the EU Commission's decision to refer the marketing authorization to a re-examination committee. This is a corporate announcement regarding regulatory developments and clinical trial status, which does not fit into specific financial reporting categories like 10-K, IR, or ER. It is a general regulatory announcement, making 'RNS' (Regulatory Filings) the most appropriate classification.
2025-04-01 Swedish
BioArctics partner Eisai presenterar simulering av framtida försäljning av Leqembi® vid sin årliga presskonferens
Earnings Release Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces that BioArctic's partner, Eisai, presented a simulation of future sales for Leqembi at their annual press conference. It contains key financial highlights (sales projections in JPY/SEK) and is dated March 25, 2025. This structure—a brief announcement highlighting key results or updates, often referencing an external presentation or report—is characteristic of an Earnings Release (ER). Although it mentions Eisai's 'annual press conference,' the document itself is a press release from BioArctic announcing Eisai's presentation, not the full annual report (10-K) or the presentation itself (IP). Given the focus on financial projections following a presentation, ER is the most appropriate classification, as it serves as the initial public disclosure of these key figures. FY 2027
2025-03-25 Swedish
BioArctic’s partner Eisai presents sales simulation for Leqembi® at its annual press conference
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces that BioArctic's partner, Eisai, published a presentation containing a sales simulation for Leqembi. It details key financial projections (sales targets for FY 2027) and provides a link to the external presentation. This structure—a brief announcement summarizing external material and providing context—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on financial projections (sales simulation) released by the partner, it aligns best with an Earnings Release (ER) which covers key financial highlights for a period, even if the underlying data comes from a partner's conference. It is not the full report (10-K or IR), nor is it a transcript (CT) or a formal regulatory filing like a DVA or DIRS. It is a press release announcing financial outlook information.
2025-03-25 English
BioArctic erhåller särläkemedelsklassificering för exidavnemab i USA
Regulatory Filings Classification · 1% confidence The document is a press release ("Pressmeddelande") announcing that BioArctic AB's drug candidate, exidavnemab, received Orphan Drug Designation (ODD) from the US FDA for the treatment of Multiple System Atrophy (MSA). This type of announcement, which details a specific regulatory milestone (ODD) for a drug candidate, is a form of corporate news release. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a formal presentation (IP). Since it is a specific regulatory/development update that doesn't fit the other specialized categories (like DIRS, DIV, CAP, etc.), it falls best under the general 'Regulatory Filings' category (RNS) as a significant, non-financial regulatory event announcement, or potentially as a general announcement if RNS is reserved strictly for mandatory exchange filings. Given the options, RNS serves as the best fit for a general regulatory/corporate announcement that isn't a core financial report or a specific management/shareholder action. The document length (5611 chars) is substantial enough that it is the report itself, not just a notice of publication (RPA).
2025-03-17 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.